Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + enzastaurin + irinotecan
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of cetuximab (an EGFR inhibitor monoclonal antibody), enzastaurin (a protein kinase C inhibitor), and irinotecan (a topoisomerase I inhibitor). This regimen combines targeted therapy with chemotherapy to treat advanced cancers, particularly colorectal cancer. Cetuximab blocks EGFR signaling, enzastaurin inhibits PKC pathways, and irinotecan causes DNA damage by inhibiting topoisomerase I.
02
Targets
EGFR (Epidermal growth factor receptor)PRKCB (Protein kinase C beta)TOP1 (DNA Topoisomerase I)PKC (Protein kinase C family)
Beyond the preview
Go deeper on cetuximab + enzastaurin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + enzastaurin + irinotecan.